Literature DB >> 6201932

Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

B Oberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6201932     DOI: 10.1016/0163-7258(82)90074-2

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


× No keyword cloud information.
  43 in total

1.  Vulval ulceration associated with foscarnet.

Authors:  H B Lacey; A Ness; B K Mandal
Journal:  Genitourin Med       Date:  1992-06

2.  Treatment of CMV retinitis in an AIDS patient.

Authors:  J F Acheson; S M Shah; D J Spalton; C Bradbeer; R N Thin
Journal:  Br J Ophthalmol       Date:  1987-11       Impact factor: 4.638

3.  Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.

Authors:  Egor P Tchesnokov; Christian Gilbert; Guy Boivin; Matthias Götte
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.

Authors:  F H Noormohamed; M S Youle; C J Higgs; S Martin-Munley; B G Gazzard; A F Lant
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

5.  Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.

Authors:  S Palmer; J Harmenberg; S Cox
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Effect of foscarnet cream on experimental UV radiation-induced herpes labialis.

Authors:  D I Bernstein; C J Schleupner; T G Evans; D A Blumberg; Y Bryson; K Grafford; P Broberg; S Martin-Munley; S L Spruance
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 7.  A guide to the investigation and treatment of patients with AIDS and AIDS-related disorders.

Authors:  F A Shepherd; M M Fanning; R Duperval; J M Dupuy; B Garvey; J Joncas; N LaPointe; R Morisset
Journal:  CMAJ       Date:  1986-05-01       Impact factor: 8.262

8.  PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase.

Authors:  L Vrang; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 9.  Persistent herpes simplex virus infection and mechanisms of virus drug resistance.

Authors:  H J Field
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

10.  Quantitative analysis of antiviral drug toxicity in proliferating cells.

Authors:  K Stenberg; J Wangenheim; B Tribukait
Journal:  Cell Biol Toxicol       Date:  1986-12       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.